These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16278478)

  • 1. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.
    Loberg RD; Gayed BA; Olson KB; Pienta KJ
    J Cell Biochem; 2005 Oct; 96(3):439-46. PubMed ID: 15988761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of osteoblastic bone metastases from prostate cancer.
    Ibrahim T; Flamini E; Mercatali L; Sacanna E; Serra P; Amadori D
    Cancer; 2010 Mar; 116(6):1406-18. PubMed ID: 20108337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
    Dorai T; Dutcher JP; Dempster DW; Wiernik PH
    Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Vessella RL; Corey E
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone directed therapies for prostate cancer.
    Bradley DA; Hussain M; Dipaola RS; Kantoff P
    J Urol; 2007 Sep; 178(3 Pt 2):S42-8. PubMed ID: 17644119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).
    Ye L; Kynaston HG; Jiang WG
    Int J Mol Med; 2007 Jul; 20(1):103-11. PubMed ID: 17549396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.
    Logothetis CJ; Navone NM; Lin SH
    Clin Cancer Res; 2008 Mar; 14(6):1599-602. PubMed ID: 18347159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of therapeutic agents to bone to treat metastatic cancer.
    Bagi CM
    Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET; Brown J
    J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic process of prostate cancer metastasis to bone.
    Tantivejkul K; Kalikin LM; Pienta KJ
    J Cell Biochem; 2004 Mar; 91(4):706-17. PubMed ID: 14991762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
    Saad F; Lipton A
    Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The critical role of the bone microenvironment in cancer metastases.
    Casimiro S; Guise TA; Chirgwin J
    Mol Cell Endocrinol; 2009 Oct; 310(1-2):71-81. PubMed ID: 19616059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-modified bone marrow cell therapy for prostate cancer.
    Wang H; Thompson TC
    Gene Ther; 2008 May; 15(10):787-96. PubMed ID: 18385769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.